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ABSTRACT
Despite increased awareness of the obesity epidemic and a higher incidence of the
metabolic syndrome in humans, the incidence of obesity and its comorbidities-most
notably, type II diabetes (T2D) and cardiovascular disease (CVD)-continues to
increase. Although numerous animal models are available to study the molecular
pathways, genetics and therapeutic/prevention strategies for T2D, no model completely
recapitulates T2D or it's comorbidities in humans. Therefore, novel animal models
represent valuable research tools in understanding T2D. To develop a novel mouse
model of T2D, I characterized an outbred mouse discovered at MIT that displayed
clinical signs of diabetes. Prevalence of glucosuria in the Swiss Webster colony reached
60% (n=70) in males 8 weeks to 6 months of age. Despite severe obesity in some
females, no females were diabetic. Pathologic findings in affected males included
cachexia, dilated gastrointestinal tracts with poor muscular tone, pancreatic islet
degeneration and atrophy with compensatory metaplasia and/or neogenesis, bacterial
pyelonephritis, membranous glomerulopathy, and late-onset hepatic tumors with
macrosteatosis, microsteatosis and hydropic change in aged males. Serum insulin
correlated with blood glucose in a nonlinear pattern suggestive of islet exhaustion.
Circulating leptin levels showed a weak inverse correlation with glucose. Diabetic males
were bred with obese colony females to produce 20 male and 20 female offspring.
Prevalence of diabetes in male offspring was 80% (16/20) with a median age of onset of
18 weeks. In contrast, no diabetic females were identified, despite being significantly
more obese than males. Male predominance is likewise a feature of T2D in humans. To
our knowledge, this is the first documentation of hepatocellular carcinoma and islet
metaplasia and/or neogenesis in a spontaneous outbred mouse model of T2D. The SW
availability and histolopathologic features represent a promising new model for the
study of T2D. Further studies are required for complete molecular and genetic
characterization of the diabetic SW mouse. These studies are outlined in this thesis.
Thesis Supervisor: James G. Fox
Title: Professor of Bioengineering
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Part 1: Type 2 Diabetes in Humans
Disease Epidemiology and Significance
Despite increased awareness of the obesity epidemic and a higher incidence of the
metabolic syndrome in humans, the incidence of obesity and its comorbidities-most
notably, type II diabetes (T2D) and cardiovascular disease (CVD)-continues to
increase in both adults and adolescents (Rosenbaum, Nonas et al. 2004). In the United
States, over 20.6 million people age 20 and over have T2D representing greater than
9.6% of the total population over age 20 (NIDDK, 2005). This number is expected to rise
to over 30 million people by the year 2010. Together with diabetic complications, T21)
accounts for more than 92 billion dollars in direct health care costs in the U.S. alone
with an additional 40 billion in indirect medical expenses (Yach, Stuckler et al. 2006).
Worldwide, T2D affects approximately 150 million people (WHO, 2002), making obesity
and obesity-related disease a global epidemic. For these reasons, T2D is major public
health concern and of significant importance to the biomedical research community.
Factors in the Development of T2D and the Metabolic Syndrome
T2D has been classically described as a "glucocentric" disease, whereby hyperglycemia
is viewed as the primary disease resulting from a combination of insulin resistance and
an insulin secretory defect (beta cell dysfunction) (Unger, 2008). In the glucocentric
paradigm, the pathogenesis of diabetes centers around glucose metabolism; therefore,
treatment and prevention strategies relied on reducing hyperglycemia (high-dose
exogenous insulin therapy, etc). More recently, defects in lipid metabolism with
subsequent ectopic lipid accumulation have been implicated as primary mechanisms in
the pathogenesis of T2D and the metabolic syndrome (lipocentric) (Unger, 2008).
Recent studies have provided some evidence for the lipocentric paradigm of T2D
directly linking lipid metabolism dysfunction with insulin resistance. In 2002, Boden and
Shulman found that chronically elevated free fatty acids (FFA) coincided with the onset
of peripheral and hepatic insulin resistance, inhibiting insulin signaling by inhibition of
glucose uptake through the GLUT4 transporter in skeletal muscle. In the same study
FFA also inhibited insulin secretion. Defects in lipid metabolism also result in the ectopic
accumulation of lipids in pancreatic islets and other tissues (Lee, Hirose et al. 1994).
This may result in the lipotoxic destruction of beta cells, explaining the insulin secretory
defect that is seen with T2D (Lee, Hirose et al. 1994). Therapeutic approaches based
on a lipocentric view of T2D require addressing the underlying defects in lipid
metabolism in addition to treatment of hyperglycemia (which is primarily responsible for
microvascular and macrovascular complications of T2D).
Dysfunctional lipid metabolism links the rising obesity epidemic with the increased
prevalence of T2D and the metabolic syndrome. Metabolic syndrome (MetS) is
characterized by the presence of at least three of the following risk factors: abdominal
obesity, dyslipidemia, hypertension, insulin resistance, a pro-inflammatory state
(elevated C-reactive protein), and a prothrombotic state (elevated plasma plasminogen
activator inhibitor) (Grundy, Brewer et al. 2004). The diagnostic criteria for MetS have
been outlined by the Adult Treatment Panel III (ATPIII) as listed in table 1 (Grundy,
Brewer et al. 2004). Although the mechanisms of MetS are poorly understood,
inflammatory mediators and altered molecular processes associated with obesity and
lipid metabolism, such as defective mitochondrial function, have been implicated in the
pathogenesis.
TABLE 1. ATP III Clinical Identification of the Metabolic Syndrome (Grundy, Brewer et al. 2004)
Parameter Risk LevelAbdoina obsity(wast ircufernce
Abdominal obesity (waist circumference)
Men
Women
Triglycerides
HDL Cholesterol
Men
Women
Blood pressure
Fasting glucoseP
>102cm (>40in)
>88cm (>35in)
>150mg/dL
<40mg/dL
<50mg/dL
>130/>85 mm Hg
> 11Omg/dL
*Obesity is associated with insulin resistance and the metabolic syndrome. Abdominal obesity is more
highly correlated with the metabolic syndrome than an elevated BMI. Therefore, waist circumference is
used to identify the body weight component that puts an individual at risk for metabolic syndrome.
qJThe American Diabetes Association established a cutpoint of 2100 mg/dL, Fasting blood glucose above
this cutpoint is diagnostic of either prediabetes (impaired fasting glucose) or diabetes.
Insulin Resistance and Mitochondrial Dysfunction
Insulin resistance has been recognized as a fundamental underlying metabolic defect in
the pathogenesis of metabolic syndrome, a clustering of risk factors for heart disease
and T2D that include central obesity, dyslipidemia and hypertension (Grundy, Brewer et
al. 2004). Recent studies have linked mitochondrial dysfunction to the development of
insulin resistance and obesity in humans, demonstrating abnormal mitochondrial
structure, number and gene expression in diabetic patients and their offspring
(Wiederkehr and Wollheim 2006). Mitochondrial DNA (mtDNA) mutations are also
known to cause diabetes by affecting insulin secretion from pancreatic beta cells
(Nomiyama, Tanaka et al. 2004). Furthermore, humans and animal models of obesity
and insulin resistance show improvement in insulin sensitivity and fat metabolism
whentreated with substances that enhance the function of mitochondria (Gumieniczek,
Hopkala et al. 2006; Waugh, Keating et al. 2006) such as pioglitazone, a peroxisome
proliferator-activated receptor gamma (PPAR y) agonist.
Deciphering the role that mitochondria play in the development of insulin resistance is
confounded by the influence of obesity on mitochondrial function. Obesity in rodent
models has been shown to significantly reduce the numbers of mitochondria within
adipocytes as a result of the expanding fat droplet displacing cellular organelles (Choo,
Kim et al. 2006). Additionally, cellular lipid accumulation and changes in fatty acid
metabolism that occur in the insulin resistant state leads to an increased cellular
oxidative stress (Lin, Berg et al. 2005). The generation of free radicals further damages
the highly sensitive mitochondria, resulting in further dysfunction and promotion of
insulin resistance and thus, accumulation of cellular lipids. This leads to an
augmentative cycle of increased cellular lipid accumulation, increased free radical
damage and increased insulin resistance. Oxidative stress and the release of reactive
oxygen species (ROS) promote inflammation through activation of NF-KB and have also
been implicated in the progression of diabetes complications, including microvascular
and macrovascular dysfunction and liver disease (Lin, Berg et al. 2005).
Genetic Determinants of Type 2 Diabetes
Although T2D is complex and influenced by environmental factors such as caloric intake
and physical inactivity, it is well documented that genetic predisposition can attribute to
disease susceptibility with age-adjusted concordance rates approaching 70-80% in
monozygotic twins (Ghosh and Schork, 1996). The genetic basis for T2D is difficult to
decipher as defects in a number of molecular pathways can lead to the similar
phenotype of T2D-hyperinsulinemia, insulin resistance and hyperglycemia. Common
forms of T2D in humans are polygenic: several genetic alterations are responsible for
an increased susceptibility to T2D (Barroso, 2004). The more rare monogenic forms of
T2D, such as the family of disorders known as Maturity Onset Diabetes of the Young
(MODY), can be attributed to single mutations in known genes including HNF1b and
HNF4. Although overt mutations in these genes are less common, polymorphisms
and/or less penetrant mutations in these genes, have been attributed to increased
susceptibility to polygenic T2D (Barroso, 2004). The discovery of new candidate genes
involved in T2D may have an important impact on the understanding of molecular
pathways involved in T2D pathogenesis and novel therapeutic approaches.
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Part 2: Mouse Models of Type 2 Diabetes
The continued investigation into the key factors and mechanisms involved in the
pathogenesis of T2D in humans requires the use of animal models. Animal models of
T2D also allow the evaluation of potential therapeutics and prevention strategies.
Appropriate animal models relevant to the study of T2D in humans must either 1) have
characteristics that are similar to the pathophysiology and natural history of T2D in
humans and/or 2) should develop diabetic complications with a similar etiology as
humans (Cefalu, 2006). For decades, researchers have used numerous animal models
to fulfill these requirements including rodents, felines, swine and nonhuman primates;
however, mouse models of T2D are particularly useful. Advantages to mouse models
include a complete knowledge of the mouse genome, a short life cycle/breeding span,
ease of genetic manipulation, lower costs and ability to do longitudinal studies and
invasive testing (Cefalu, 2006).
Spontaneous Mouse Models of T2D
Mouse models used in the study of T2D include induced models, inbred mice, mice with
spontaneous genetic mutations, and genetically engineered mice. Although genetically
engineered mice are heavily represented in recent T2D literature, spontaneous mouse
models are still widely used to study obesity and T2D. Two of the most commonly used
mice are the db/db mouse (diabetes) and ob/ob mouse (obesity).
The db/db mouse (B6.Cg-m+/+Leprdb/J) was originally developed by the Jackson Labs
(1966) after discovery of a leptin receptor (Lepr db) mutation on a C57BLKS/J
background. Lack of leptin signaling results in hyperphagia with increased efficiency of
food utilization, obesity, and increased circulating leptin and insulin levels (Hummel,
Dickie et al. 1966). The mutation is recessive and only homozygous mice develop signs
of obesity or diabetes. These mice display severe obesity, insulin resistance,
hyperinsulinemia and T2D by an early age (4-8wk). The sequence of disease
progression (hyperinsulinemia 4 beta cell failure/distruction -
hypoinsulinemia/hyperglycemia) parallels the human condition. Like human T2D, the
clinical phenotype is variable dependent on genetic background and gender (males >
females) (Jackson Labs, accessed 2008). The db/db mouse is particularly valuable in
that it develops diabetic comorbidities that mirror the human conditions including
diabetic glomerulopathy with mesangial matrix expansion, glomerular hypertrophy,
altered glomerular function and albuminuria (Sharma, McCue et al. 2003). Other
reported conditions include heart diseas and diabetic dyslipidemia (Kobayashi, Forte et
al. 2000). Despite their widespread utility in diabetes research, db/db mice, unlike
humans, do not develop marked pancreatic pathology or severe comorbid diseases and
display complications of altered leptin metabolism such as infertility (hypogonadism),
altered thermoregulation, marked hyperphagia and a shortened lifespan. Also, they
represent a monogenic form of diabetes which is uncommon in human populations.
ob/ob Mice (obesity) (B6.V-Lepob/J) have a mutation at chromosome 4 and are similar
to db/db mice in that they represent a model of altered leptin metabolism (truncated,
inactive leptin product), obesity and insulin resistance. The phenotype is considered
much less severe than db/db mice with ob/ob mice exhibiting obesity with hyperphagia,
glucose intolerance, hyperinsulinemia and transient hyperglycemia (Jackson
Laboratories, accessed 2008). However, the phenotype is highly dependent on genetic
background and mice with a more severe diabetic phenotype are available. ob/ob Mice
also develop cormorbidities associated with obesity and diabetes including peripheral
neuropathy (Drel, Mashtalir et al. 2006), heart disease, delayed wound healing and
skeletal abnormalities (Jackson Laboratories, 2008), and fatty liver disease that may
occasionally progress to neoplasia (Anstee and Goldin, 2006). Drawbacks to ob/ob
mice as a model of T2D in humans are similar to db/db mice.
Other spontaneous mouse models of T2D include the Nagoya-Shibata-Yasuda (NSY),
KK mouse and the NONcNZO10/LtJ mouse. These mice vary in age-of-onset and in
their presentation of T2D but all share similar features of moderate obesity and insulin
resistance, while the NSY and NONcNZ10/LtJ mice develop hyperglycemia. The NSY
mouse, developed through the selective inbreeding for glucose intolerance in outbred
Jcl:ICR mice, develops signs of T2D in an age-dependent manner with a higher
prevalence of males affected than females (98% v 13% respectively) (Ueda, Ikegami et
al. 1994). NONcNZO10/LtJ also develop signs of mild to moderate obesity and diabetes
dependent on age (maturity-onset) (Cho, Kim et al. 2007). The development of
hyperglycemia and diabetes in KK mice is body weight dependent (Ikeda, 1994).
Notably the NSY, KK and NONcNZO10/LtJ mice are all polygenic models of T2D
compared with the monogenic db/db and ob/ob mouse models, mirroring human T2D.
Despite the utility of mouse models in T2D research, none of these mice completely
recapitulate T2D and it's comorbidities in humans. Importantly, a major drawback of
mouse models of T2D is the apparent lack of islet pathology observed in humans
(Cefalu, 2006). Therefore, novel animal models are needed. Part 3 in this paper
describes one such model discovered by the Division of Comparative Medicine at MIT.
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Abstract
Genetic mutations resulting in obesity and type 2 diabetes mellitus (T2D) are described
for both inbred and outbred mice. However, no known mouse model completely
recapitulates human T2D and its comorbidities. We identified a cohort of obese, male,
outbred Swiss Webster (SW) mice as polyuric, polydipsic, glucosuric and
hyperglycemic. Prevalence of glucosuria in the SW colony reached 60% (n=70) in
males 8 weeks to 6 months of age. Despite severe obesity in some females, no females
were diabetic. Pathologic findings in affected males included cachexia, dilated
gastrointestinal tracts with poor muscular tone, pancreatic islet degeneration and
atrophy with compensatory metaplasia and/or neogenesis, bacterial pyelonephritis,
membranous glomerulopathy, and late-onset hepatic tumors with macrosteatosis,
microsteatosis and hydropic change in aged males. Serum insulin correlated with blood
glucose in a nonlinear pattern suggestive of islet exhaustion. Circulating leptin levels
showed a weak inverse correlation with glucose. Diabetic males were bred with obese
colony females to produce 20 male and 20 female offspring. Prevalence of diabetes in
male offspring was 80% (16/20) with a median age of onset of 18 weeks. In contrast, no
diabetic females were identified, despite being significantly more obese than males.
Male predominance is likewise a feature of T2D in humans. To our knowledge, this is
the first documentation of hepatocellular carcinoma and islet metaplasia and/or
neogenesis in a spontaneous outbred mouse model of T2D. The SW availability and
histolopathologic features represent a promising new model for the study of T2D.
Introduction
The incidence of obesity and its comorbities-most notably metabolic syndrome, type 2
diabetes (T2D) and cardiovascular disease (CVD)-continues to increase in both adults
and adolescents (33). Metabolic syndrome is defined by the presence of at least three
of the following risk factors: abdominal obesity, dyslipidemia, hypertension, insulin
resistance, a proinflammatory state (elevated C-reactive protein), and a prothrombotic
state (elevated plasma plasminogen activator inhibitor) (19). A majority of metabolic
syndrome patients are obese and insulin resistant, conferring an increased risk for
T2D(19). Humans with T2D have a functional insulin deficiency characterized by fasting
hyperglycemia due to peripheral insulin resistance combined with an insulin secretory
defect (i.e. inability to increase beta cell mass).
An estimated 5-10% of the U.S. population suffers from T2D (18, 37) and is at
increased risk for developing microvascular and neuropathic complications,
macrovascular disease, microbial infections and neoplasia. Recently, several
epidemiological studies have shown an increased risk of hepatocellular carcinoma
(HCC) in patients with T2D in the absence of viral hepatitis (11, 13). HCC in humans
with diabetes is associated with underlying nonalcoholic fatty liver disease (NAFLD), a
common finding in patients with obesity and metabolic syndrome. NAFLD can progress
to steatohepatitis (NASH) with cirrhosis and eventual neoplastic transformation. While
the direct link between diabetes and HCC remains unknown, underlying chronic liver
disease has been implicated in the development of both diabetes and HCC.
Several spontaneous and induced genetic mutations resulting in varying degrees of
obesity and diabetes have been described in mice, making them popular models in
diabetes research (2, 29). Mutation of the leptin or leptin receptor gene produces
obesity and T2D in the ob/ob and db/db mouse respectively. The db/db mutation is
available on a variety of mouse strain backgrounds, is well characterized, and displays
many of the comorbities of T2D found in humans, including cardiovascular disease,
renal disease and neuropathies (31, 35, 42). However, these mice represent a
monogenic model demonstrating features related to leptin resistance, including morbid
obesity, hyperphagia, and alterations in thermoregulation and fertility. In contrast to
popular mouse models of diabetes, common forms of human T2D are considered
polygenic disorders, occurring through the simultaneous action of several genes and
rarely involving alterations of the leptin/leptin receptor axis (47).
We recently identified a cohort of male, outbred Swiss Webster (SW) mice in a breeding
colony that required frequent cage changes due to urine-soaked bedding, and frequent
water bottle changes (i.e. polyuria/polydipsia). The SW breeding colony at the
Massachusetts Institute of Technology (MIT) is maintained to provide mice for the
embryo transfer program and occasionally for sentinel animals as part of the rodent
health monitoring program. At the time of the study, the colony had been closed for
approximately two years with a random breeding strategy in place. Five males were
isolated from the colony for further study. Metabolic comparisons with age-matched,
control males showed markedly increased urine production and water consumption in
the affected mice; however, there were no significant differences in food consumption or
body weight (data not shown). Additionally, affected mice were glucosuric, and serum
chemistry analysis with insulin levels on one mouse revealed hyperglycemia,
hypercholesterolemia, azotemia and hyperinsulinemia-signs consistent with both
metabolic syndrome and T2D in humans. The affected mice were subsequently bred to
females from the SW colony to produce 20 male and 20 female offspring. The current
study describes the clinicopathologic features of T2D in these SW offspring as well as
the prevalence and characterization of this disease in the SW breeding colony where
the disease was first recognized.
Materials and Methods
Animal sources and husbandry
Five, 18-week-old, male, outbred Swiss Webster (SW) mice and 10, 8-week-old, female
SW mice were obtained from the breeding stock of the MIT Division of Comparative
Medicine mouse breeding program (closed breeding program for a minimum of 2
years), and subsequently bred to produce 20 male and 20 female offspring (Fls). SW
offspring were weaned at 4 weeks of age and separated by sex into groups of four.
These mice have continued to be inbred, and mice up to generation 7 are included in
the aging part of this study. Additional diabetic and nondiabetic male, and nondiabetic
female SW mice were selected from existing sentinel mouse cages placed in mouse
rooms on the MIT campus.
Mice were housed in polycarbonate microisolator cages on hardwood bedding
(PharmaServ, Framingham, MA) under specific pathogen free (SPF) conditions (free of
Helicobacter spp., Citrobacter rodentium, Salmonella spp., endoparasites, ectoparasites
and known murine viral pathogens) in an Association for the Assessment and
Accreditation of Laboratory Animal Care International (AAALAC) accredited facility.
Mouse rooms were kept at constant temperature and humidity on a 12:12 hour light to
dark cycle, and mice were provided standard rodent chow (Purina Mills, St. Louis MO)
and water ad libitum. All protocols were reviewed and approved by the MIT Committee
on Animal Care. Mice were euthanized by CO 2 inhalation in accordance with guidelines
set by the American Veterinary Medical Association (1).
Clinicopathology of colony Swiss Websters
The presence of glucosuria was determined by collection of urine from nonanesthetized
mice onto glucose urine dipsticks according to manufacturer's instructions (Diastix®,
Bayer Corporation, Elkhart, IN). Based on the presence or absence of glucosuria, mice
were defined as diabetic or nondiabetic.
Fifteen diabetic male colony SW mice and five nondiabetic colony SW mice (three
males, two females) approximately 6 months of age, were selected for necropsy. Non-
fasting blood glucose concentrations were measured from 10/15 glucosuric and 5/5
non-glucosuric mice using the OneTouch Basic glucometer (Lifescan, Inc. Milpitas, CA)
from whole blood collected via terminal cardiac puncture. Whole blood was analyzed for
complete blood count (CBC) and serum was submitted to a reference laboratory
(IDEXX, North Grafton, MA) for biochemical analysis, insulin concentration and insulin
to glucose ratio. Urine was collected via cystocentesis and submitted for complete
urinalysis and aerobic culture.
Breeding experiments
To assess the reproductive performance of diabetic mice, five 6-month-old, diabetic
male SW mice and ten nondiabetic females were selected from the breeding colony and
bred to produce 20 male and 20 female F1 offspring.
Selected F1 brother-sister matings were undertaken to gauge reproductive viability and
to establish diabetic Swiss Webster (dSW) and nondiabetic Swiss Webster (ndSW)
lines. For diabetic mice, males were selected for breeding at the first positive test for
glucosuria and mated to the heaviest female from the same litter. In nondiabetic mice,
the smallest male and female were selected for breeding. Subsequent litters were
inbred using the same paradigm, with mice up to generation 7 included in this study.
Pathology and immunohistochemistry
Tissues were collected at scheduled necropsy from diabetic and nondiabetic parent
colony SW, as well as selectively bred dSW and ndSW lines. For routine
histopathology, tissues were fixed in 10% neutral buffered formalin, routinely processed
and embedded, sectioned at 4tm, and stained with hematoxylin and eosin (H&E).
Formalin-fixed, whole pancreata were sectioned at 4ipm to include the gastric (head)
and duodenal (tail) portions for immunohistochemical staining using guinea pig anti-
swine insulin antibody (30) (DakoCytomation, Carpinteria, CA) at 1:150 on an
automated immunostainer as previously described (32).
Bacteriology
Urine collected via cystocentesis, and aseptically collected tissue samples from gross
lesions of the kidney, urinary bladder, liver, and/or gallbladder were submitted in
trypticase-soy broth (TSB) for aerobic culture at 370C when appropriate.
Establishment and characterization of diabetic/nondiabetic Swiss-Webster (dSW/ndSW)
Diabetic SW (dSW) offspring produced during breeding experiments with the diabetic
colony SW males were characterized during development to determine the onset of
clinical signs of obesity and diabetes. Mice were weaned at four weeks of age and
separated by gender into 10 groups of four mice/group to total 20 males and 20 females
(at least four males and four females were included from each fertile sire). At weaning,
body weight was recorded and mice were tested for the presence of glucosuria using
the urine dipsticks. Urine glucose was reassessed at 10, 18, 26, and 30 weeks to
determine the median age of onset of glucosuria. Body weight was recorded at one
week intervals until week nine and then at week 17, 19, 22, 26 and 30. Blood was
collected at 13 and 30 weeks via the retro-orbital sinus, from nonfasted mice
anesthetized with 2% isoflurane in oxygen for determination of blood glucose using the
OneTouch Basic glucometer (LifeScan Inc, Milpitas, CA). Serum insulin and leptin
concentrations were measured from the 30 weeks serum samples using Rat/Mouse
Insulin and mouse leptin ELISA kits respectively (LINCO Research, St. Charles, MO)
according to the manufacturer's instructions.
Glucose tolerance testing was performed to confirm diabetic status in selected diabetic
and nondiabetic male and female mice. After a 12-14hr fasting period, baseline blood
glucose measurements were obtained using whole blood collected from the tip of the
tail in unanesthetized mice. Then, 1.5mg glucose per gram body weight was
administered via intraperitoneally injection (75mg/mL solution) and serial blood samples
were obtained and analyzed at 15min, 30min, 60min, 90min and 120min post injection.
Statistical Methods
Body weights and serum chemistries were analyzed by one-way analysis of variance
(ANOVA) with Tukey's post test. Median survival was calculated by Kaplan-Meier
survival curve analysis. Serum insulin and leptin concentrations were compared to
blood glucose concentration by nonlinear and linear regression analysis respectively.
Glucose tolerance testing was analyzed by determination of the areas under the curve
(AUC). Mean AUCs for diabetic and nondiabetic groups were compared using an
unpaired t test. P values <0.05 were considered significant. All analyses utilized
GraphPad Prism version 4.0 for Windows (GraphPad Software, San Diego, CA).
Results
Characterization of diabetes in dSW mice
Prevalence of diabetes in the male dSWs was 80% (n=20) with a median age of onset
of 18 weeks (Figure la), and no diabetic females were identified. Mean, nonfasting
blood glucose of diabetic male offspring at 30 weeks was 451.3±93.9mg/dl and differed
significantly from nondiabetic male and female offspring (163.7±11.3 and
171.3±25.2mg/dl, respectively P<0.01) (Figure l b). Female offspring were significantly
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Figure 1: Characterization of diabetes in male and female dSWs. A) Onset of glucosuria in maledSWs. Kaplan-Meier survival curve where onset of glucosuria was considered as event. Mediansurvival in male mice (n=20) was 18 weeks of age. Throughout the test period, no glucosuric females(n=20) were identified. B) Hyperglycemia in male dSWs. Nonfasting, whole blood glucose concentrationwas significantly higher in male dSWs (n=20) compared with in age-matched dSW females (n=20) atboth 13 and 30 weeks of age as measured using a bedside glucometer. Blood glucose concentrationwas more variable in male mice compared with females with a greater proportion of males showingsignificant hyperglycemia at 30 weeks of age compared to 13 weeks. Mean values with standard errormarains are disolaved. 24
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heavier than males at 53.9±5.7g and 48.2_+6.0g respectively (P<0.05) at 30 weeks of
age (Figure 2).
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Figure 2: Growth rate in dSWs.
Body weight was measured over
time in male (n=20) and female
(n=20) dSW mice. At 30 weeks of
age, diabetic male dSW were
significantly heavier than
nondiabetic male dSW. Although
weanling males were initially
heavier than females, at 30 weeks
of age, females were significantly
heavier than males. Mean values
with standard error margin are
displayed.
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Serum insulin concentrations for dSWs were measured using a rat/mouse insulin ELISA
kit (Lincoplex). Serum insulin concentration was highly variable between mice, with no
significant differences observed between the mean values for diabetic (males) and
nondiabetic (male and female) mice.
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concentrations in dSW males at 7-
9mths of age (Figure 3). Insulin
concentrations were increased in dSW
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blood glucose concentrations, and
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Figure 3: Insulin and blood glucose concentrations
in male dSWs (n=20) at 7 months of age. Nonfasting
serum insulin measured by ELISA showed a nonlinear
correlation with whole blood glucose concentration. Male
dSW with mild hyperglycemia showed elevated insulin
concentrations compared to males with marked
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were highest in those mice with a blood glucose concentration of approximately
300mg/dl (coincident with an onset of overt glucosuria). Diabetic mice with blood
glucose concentrations above 300mg/dl, showed declining insulin concentrations that
were inversely proportional to blood glucose concentration.
Glucose tolerance testing in fasted mice revealed elevated glucose curves in response
to glucose challenge in diabetic male mice compared with nondiabetic mice. Mean area
under the curve (AUC) for diabetic mice was significantly higher than nondiabetic mice
(25,420±1,501 and 13,060±992 respectively P<0.0005; Figure 4), consistent with
glucose intolerance in diabetic SW males. Blood glucose measurements in mice over
12 months of age were difficult to interpret due to the high prevalence of liver tumors in
diabetic males. The presence of liver tumors occasionally coincided with a reversion to
euglycemia or hypoglycemia in some mice with previously noted hyperglycemia.
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Figure 4: Glucose tolerance testing in aged dSW and ndSW. A) Glucose tolerance curves revealed
elevated baseline with delayed return to baseline in diabetic males (solid lines) compared with
nondiabetic males (broken lines). B) AUC measurements obtained from the curves in panel A were
significantly higher in diabetic compared to nondiabetic males.
Serum leptin concentrations, measured by a mouse leptin ELISA kit (Lincoplex) were
also highly variable between mice, and no significant differences in mean
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concentrations were observed between diabetic and nondiabetic mice
(6.821±t6.920ng/ml and 8.766±4.385ng/ml respectively). However, serum leptin
concentration showed a significant, inverse linear correlation with blood glucose
concentration in diabetic 7-month-old, dSW males (Figure 5).
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Figure 5: Serum leptin in dSW at 7 months of age. Nonfasting serum leptin concentrations asmeasured by ELISA were highly variable among diabetic male (n=17), nondiabetic male (n=7) andfemale (n=4) dSW with no significant differences observed. In diabetic male dSW, leptinconcentrations showed a weak inverse correlation with whole blood glucose concentration. Markedlyhyperglycemic males also showed decreased adipose stores and body condition which may explaindecreased leDtin concentrations.
Diabetic dSW male and female mice produced viable offspring (average 12 pups) when
bred at less than 6 months of age and prior to the onset of moderate obesity in the
females (<50g). No females became pregnant when bred after 6 months of age (n=3);
however, dSW males remained reproductively viable past 8 months of age (8/8 tested
males were capable of impregnating females and producing offspring).
Diabetic parent colony Swiss Webster (SW) mice
Over a sampling period of one week, the prevalence of diabetes (defined as blood
glucose >300mg/dl with glucosuria) in the SW mouse breeding colony was 60% (42/70)
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in males between 8 weeks and 12 months of age (average age >6 months). The
prevalence of diabetes in male SW housed in a corridor separate from the breeding
colony was 36% (17/47). However, the average age of males housed in the second
corridor was <4 months and no breeding animals were tested. No females from either
colony tested positive for glucosuria (n=40).
Serum biochemical data were analyzed in nine diabetic SW males and three
nondiabetic SW males, approximately 6 months of age. The mean blood glucose
concentration in diabetic (i.e. glucosuric) males was significantly higher than nondiabetic
males at 396.2±14.4mg/dL and 235.3±35.59mg/dL respectively (P = 0.0005). Diabetic
males had significant elevations in serum alanine aminotransferase (ALT), blood urea
nitrogen (BUN), phosphorus and lipemic index compared with nondiabetic males
(Figure 6). These alterations were consistent with early pre-renal or renal insufficiency,
hepatocellular injury and hyperlipidemia.
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Figure 6: Biochemical characterization
of diabetes in colony SW males. A)
Diabetic male SW (n=9) mice showed
significantly higher nonfasting, whole blood
glucose concentration (A) and serum
lipemic index (B) when compared with
nondiabetic male SW (n=3). Serum alanine
aminotransferase (ALT) and blood urea
nitrogen (BUN) were also significantly
elevated (C and D, respectively) in diabetic
male SW, but not serum creatinine (data
not shown), suggesting prerenal or early
renal azotemia. Mean values with standard
error margin are displayed.
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Gross pathology
Gross and histologic lesions in diabetic male
mice, whether from the parent colony or dSW
line, were similar in character. Diabetic male
mice with advanced disease (blood glucose
>300mg/dl, urine glucose positive) were
distinguishable grossly from nondiabetic mice
based on decreasing body condition. External
gross findings included urine staining of the
perineum and ventrum, unkempt hair coats,
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avuubr iiia uSrension ana aecreasea boay Figure 7: Gross pathology of diabetic
condition scores (41). Body condition scores colony SW males. A) Diabetic male colonySW mice with advanced disease were grossly
distinguishable from nondiabetic males,averaged 2 out of 5 as ascertained by showing decreased body condition scores,
unkempt fur and a pot-bellied appearance due
palpation of the iliac bones and sacral to enlarged, ingesta-filled gastrointestinal
tracts. B) The ceca of diabetic males (right)
were enlarged and flaccid compared with age-prominences. Despite poor body conditions, matched nondiabetic males (left). Gross
findings suggested decreased gastrointestinaldiabetic mice maintained body weight due to motility.
abdominal distension (Figure 7) caused by enlarged, flaccid, ingesta-filled
gastrointestinal tracts. The abdominal musculature of diabetic mice was thin and
transparent, and the cecum markedly dilated and filled with ingesta, when compared
with age- and gender-matched, nondiabetic controls (Figure 7). Dilation of the stomach
and small intestine was evident less frequently. Diabetic males in the initial stages of
disease showed increased body weight and abdominal fat deposition compared with
nondiabetic males.
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Kidneys of mice with ascending urinary tract infections were enlarged and irregularly
disfigured by pelvic and, less frequently, cortical pale-to-yellow caseous abscesses up
to 5 mm in diameter. Mice with marked pyelonephritis became moribund, exhibiting
hunched posture, reluctance to move, poor body condition and an unkempt
appearance. Ascending urinary tract infections were a significant cause of morbidity and
mortality in the diabetic cohort. One mouse had uroabdomen and was suspected to
have ruptured the ureter near the renal pelvis. Diabetic mice also showed mildly to
moderately enlarged kidneys bilaterally with mild dilation of the renal pelvices and
ureters (hydronephrosis and hydroureter).
Diabetic mouse livers appeared moderately enlarged and pale compared with
nondiabetic mouse livers. 75% of diabetic males, 12-18 months of age (n=12) had
grossly visible hepatic tumors. Liver tumors were not observed in age-matched
nondiabetic males (n=4) or females (n=5) (Odds ratio = 24.43, P = 0.008). Tumors
ranged from 0.1 x 0.1cm to 1.5 x 2.0cm. Affected mice frequently exhibited multiple
tumors affecting multiple liver lobes, with only 3 out of 12 affected mice showing a single
tumor. Interestingly, obese females but not males from the parent colony infrequently
developed nonobstructive pigmented gallstones as determined by microscopic
morphology and polarization pattern.
Histopathology
The pancreata of diabetic and nondiabetic mice were scored from 0 (none) to 4 (severe)
for islet haphazard arrangement and vacuolation, and 0 (focal) to 4 (severe) for
histologic changes consistent with islet
metaplasia (Figure 8). Virtually all male
mice, whether clinically diabetic or not,
displayed some degree of islet cell
pleomorphism and atypia. Enlarged islets
and mega-islets were occasionally seen in
diabetic male mice (Figure 9). Islet
metaplasia was defined by incomplete de
novo parenchymal sublobulation, well
removed from ductular regions, with a
mixture of cells displaying islet, acinar,
and/or intermediate morphology, (Figure 9).
characteristic histologic pattern, these regions
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Figure 8: Pancreatic pathology scores in
diabetic (n=15) and nondiabetic (n=4) colony
SW mice. The pancreata of diabetic and
nondiabetic mice were scored from 0 (none) to 4
(severe) for islet haphazard arrangement,
vacuolation, inflammation and changes
consistent with islet metaplasia. Islet metaplasia
was only observed in diabetic males.
Because of the clinical history and
were interpreted as zones of exocrine
pancreatic acinar cells undergoing metaplasia to an islet phenotype. In other instances,
cells with an islet phenotype were observed in small, poorly defined clusters adjacent to
ducts. These foci were defined as islet neogenesis based on immature morphology and
location near the normal site of islet development. In some mice, radiating cords of islet-
type cells emanated from periductular regions and extended haphazardly into
surrounding acinar regions (Figure 9). In many diabetic male mice, pancreatic ducts
were ectatic and filled with secretory material, suggesting hypersecretion and/or outflow
obstruction. Leakage from ectatic ducts may have resulted in a sclerosing pancreatitis
observed in one aged, diabetic male (Figure 9). Although remarkable in presentation
and variety, pancreatic islet histopathology did not correlate with glucosuria nor serum
-- -- ar,
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glucose or insulin levels in mice for which data were available. No significant pancreatic
lesions were observed in female mice regardless of body weight or blood glucose level.
Diabetic mice were at increased risk for renal disease including increased numbers of
mesangial cells, mesangial matrix expansion, and dilated renal pelvices as listed in
Table 2. Kidney lesions in diabetic mice were more severe with advancing age,
displaying membranous glomerulopathy characterized by decreased erythrocyte profiles
and thickened endothelial basement membranes (Figure 9). A portion of diabetic mice
developed ascending pyelonephritis as evidenced by kidney abscessation, pyuria and
bactiuria. Intralesional bacterial colonies were readily apparent by both H&E and tissue
Gram's stain.
Table 2: Kidney lesions in diabetic and nondiabetic colony SW mice at -6mths
Numbers of Mice (n=20)
Diabetic (n=16) Nondiabetic (n=4)
Males (n=16) Males (n=2) Females (n=2)
Increased mesangial cells 10 1 0
Mesangaimatrix expansion 9 1 0
Pyelonephritis 2 0 0
Livers of aged (>1 year) diabetic males (n=12) and less frequently in mice less than one
year of age exhibited moderate to severe centrilobular glycogen-associated hydropic
degeneration superimposed over microvesicular and macrovesicular steatosis, and
several had hepatocellular carcinoma. Steatosis was centrilobular in distribution and
adjacent mid-zonal hepatocytes frequently demonstrated cellular atypia and an
increased mitotic rate. Lipid-associated changes were histologically consistent with
human non-alcoholic fatty liver disease (NAFLD). Liver tumors in diabetic males weire
consistent with HCC displaying cellular atypia and pleomorphism, local invasion into
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Figure 9: Histopathologic and immunohistochemical features of SW T2D. (a) Normal pancreatic
island from obese but nondiabetic female mouse. (b) Islet from diabetic male demonstrating irregular cell
arrangement and variable cytoplasmic swelling by granular to fibrillar pale eosinophilic material. (c) Insulin
immunohistochemistry (IHC) demonstrating uniform distribution of insulin in female pancreatic islet. (d)
Insulin IHC of diabetic male pancreatic islet shows patchy punctate staining in a subset of cells. (e) Islet
metaplasia characterized by newly encapsulated sublobule containing a mixture of exocrine and endocrine
pancreatic cell phenotypes. (f) Insulin IHC of islet metaplasia highlights irregular expression limited. to
endocrine cell phenotypes (arrows). (g) Female pancreas demonstrating normal ducts (arrows). (h)
Diabetic male pancreas with ectatic ducts filled with secretory material (arrows) suggesting hypersecretion
and/or outflow impairment. (i) Mega-islet in diabetic male. (j) Sclerosing pancreatitis in diabetic male
characterized by replacement of acinar cells with wide bands of fibrous connective tissue, and mixed
inflammatory cells surrounding ducts and infiltrating septa. (k) Normal glomeruli from female kidney. (I)
Membranous glomerulopathy of kidney in diabetic male characterized by decreased erythrocyte profiles
and thickened endothelial basement membranes (wireloop capillaries; arrows). (m) Liver of aged (>1 year)
diabetic male demonstrating mixed fatty and hydropic hepatocyte degeneration with large lipid vacuoles
(macrosteatosis; "M"), small lipid vacuoles (microsteatosis; "m"), and cloudy swelling characteristic of
glycogen accumulation ("G"); adjacent hepatocytes had an increased proliferative index (mitotic figure at
arrow). (n) Clear cell hepatocellular carcinoma (HCC; large arrow) arising from liver lobe of aged male
mouse with preexisting centrilobular fatty and hydropic degneration (small arrows). (o) Solid nodule
(arrow) within larger mixed phenotype HCC. (p) Trabecular and pelioid tumor differentiation (arrow) within
mixed HCC. Hematoxylin & eosin (a, b, e, g-p), insulin IHC (c, d, f); bar = 25 gm (a-d, k, 1), 50 gm (e; f,
m), 250 gim (g-j), 500 gm (n-p).
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surrounding normal parenchyma, and a high mitotic index. HCCs were often the solid
variant comprised primarily of clear cell hepatocytes. Mixed tumors with sublobules
comprised of eosinophilic cells in a trabecular or pelioid pattern were also represented
(Figure 9). Compared to diabetic males, no females (P = 0.0079) or nondiabetic males
(P = 0.0667) developed liver tumors. Neither hepatitis nor fibrosis, were significant
features in any of the mice, and no significant hepatic lesions were observed in SW <6
months of age.
No significant cardiovascular or neurologic lesions were observed in these mice by the
age of 12 months.
Bacteriology
Positive cultures obtained from urine were primarily mixed infections, and included
Escherichia coli, Staphylococcus spp, Proteus spp, and Enterobacter aerogenes.
Occasionally, Staphylococcus spp were isolated from kidney, mandibular and
musculoskeletal abscesses.
Immunohistochemistry
In diabetic male SW mice, degenerate islets showed patchy insulin positive cells and
poor staining intensity compared with nondiabetic animals (Figure 9). Islet cells positive
for insulin were generally larger than surrounding cells and had prominent, vesicular
nuclei, suggestive of compensatory hypertrophy. Insulin IHC confirmed the presence of
islet metaplasia by demonstrating isolated insulin-producing cells within the exocrine
pancreas and/or foci of insulin-producing cells admixed with exocrine-like cells in poorly
defined islet-like sublobules as described previously (Figure 9). Small nests of insulin-
positive cells located adjacent to pancreatic tubules were suspected to represent islet
neogenesis (6), although specific cell lineage could not be determined morphologically.
All female SW mice showed uniform, robust staining for insulin within islets. Isolated
insulin-positive cells were extraordinarily rare in the exocrine pancreas of nondiabetic
mice.
Discussion
We describe a cohort of outbred, male Swiss Webster mice and their offspring with
clinical and biochemical signs consistent with the metabolic syndrome and type 2
diabetes mellitus (T2D) in humans, characterized by insulin resistance and abdomirial
obesity. Clinical signs of T2D in male SW mice, including polyuria, polydipsia and
glucosuria were evident at an average age of 18 weeks. In these mice, a high incidence
of diabetes was observed, approaching 60% in colony SW (n=70) and 80% in dSWs
(n=20) by 30 weeks of age. The high prevalence of diabetes in the MIT SW breeding
colony is suggestive of a founder effect-a loss of genetic variability initiated when the
MIT colony was established from a relatively small number of animals from the original
population of SW mice obtained from an outside source. Although mice from this colony
are not typically assigned to research protocols, the affect of diabetes on the utility of
SW mice for rodent health monitoring remains unknown. To limit the potential impact on
rodent health, the MIT breeding colony was depopulated and renewed with additiontal
mice from a different commercial vendor.
Initially, diabetic males showed increased body weight and grossly observable fat stores
within the abdominal cavity compared with nondiabetic males; however, advanced
disease resulted in declining body condition and loss of mesenteric and epididymal fat
pads. Fasting glucose tolerance tests performed in diabetic mice (nonfasting blood
glucose > 300mg/dl, glucosuria positive) confirmed altered glucose homeostasis
compared with nondiabetic mice showing elevated glucose response curves with a
delayed return to baseline. Although mice were at variable stages of disease during
glucose tolerance testing (10-13 months of age), previously determined nonfasting
hyperglycemia and glucosuria were predictive of elevated glucose response curves,
despite the presence of liver tumors.
Diabetic colony SW and dSW males showed variable insulin levels that displayed a
nonlinear correlation with blood glucose concentration. In the diabetic males (blood
glucose >300mg/dl), insulin levels were inversely proportional to the degree of
hyperglycemia. Elevated serum insulin concentrations were seen at relatively mild
stages of hyperglycemia. Mice with high insulin and mild hyperglycemia may reflect a
compensated stage of diabetes with pancreatic beta cells producing increased insulin in
response to insulin resistance. Increased beta cell mass has been described inr
numerous mouse models of spontaneous T2D, including the CBA/Ca, db/db mouse,
and high-fat diet models(15, 27, 36), as well as humans (7). In our outbred cohort,
interindividual differences in pancreatic histopathologic presentation among diabetic
males obscured any potential relationships between islet morphology and circulating
insulin levels. Beta cell degeneration and subsequent 'burnout' could result from
glucotoxicty, lipotoxicity or defective stimulation. This possibility is supported by the
observation that beta cell degeneration was not seen in female mice. Importantly, beta
cell degeneration with apoptosis and increasing levels of hyperglycemia have been
described in diabetic rodents and humans and are important in the pathogenesis of T2D
(3, 10, 25).
Although not directly correlated with circulating insulin or leptin levels, pancreata from
male diabetic mice had mild to severe islet cell degeneration with islet metaplasia.
Regions of islet metaplasia were presumed to represent the transdiffereniation of
pancreatic cells from an exocrine to an endocrine phenotype. Islet neogenesis, defined
by poorly arranged islet cells in the normal periductular location, is reported in rodent
models of pancreatic injury (streptozotocin administration, ischemia, subtotal
pancreatectomy), transgenic mice, and in spontaneously hyperglycemic rats (6, 28, 39).
Additionally, neogenesis of human pancreatic islets has been described in obese and
diabetic subjects (10). However, to our knowledge, it has not been previously reported
in spontaneous outbred mouse models of diabetes mellitus. Islet neogenesis is thought
to occur as a compensatory mechanism to increase beta cell mass and number, due to
increased insulin demands.) The presence of histologic features such as the formation
of megaislets and transdifferentiation/neogensis coupled with qualitatively inadequate
production of insulin in from these islets (patchy, sparse insulin staining by IHC
compared with nondiabetic animals) is suggestive of a potential defect in islet
production of insulin. However, the physiologic mechanisms underlying these
compensatory responses are incompletely understood. Because this model shows a
robust pancreatic islet cell response to the insulin resistant state, it should prove useful
in exploring these mechanisms.
Similar to humans, the most notable features of the metabolic syndrome in the SW and
dSW were abdominal obesity and insulin resistance. While a significantly higher lipemic
index was observed in diabetic males compared with nondiabetic males, no grossly
identifiable atherosclerotic plaques were seen in the proximal aorta, and systolic blood
pressures were not measured. More extensive studies are required to fully ascertain the
risk for cardiovascular disease in this model. Unlike widely used mouse models of the
metabolic syndrome, the diabetic SW are maintained on a standard rodent diet, as
opposed to experimental "westernized" or high fat diets. While environmental factors
cannot be ignored, the SW and dSW may prove useful in exploring genetic mechanisms
behind the development of the metabolic syndrome.
Diabetes mellitus, obesity and hepatosteatosis are known risk factors for development
of HCC in human populations, predominantly in males (11, 13, 20). Liver tumors
consistent with clear cell hepatocellular carcinoma and mixed HCC were seen in 75% of
aged, diabetic male SW and dSW (n=12) associated with a background macrosteatosis,
microsteatosis and hydropic change consistent with non-alcoholic fatty liver diseaSe
(NAFLD) in humans (14). Studies of NAFLD in obese ob/ob mice have shown evidence
of chronic liver injury with increased hepatocyte proliferation and decreased
hepatocellular apoptosis that may explain an increased incidence of HCC in ob/ob mice.
However, like the dSW mice, ob/ob mice do not develop evidence of hepatitis or
cirrhosis (45). Questions remain as to the role of hyperinsulinemia in carcinogensis.
High insulin levels, known hepatocyte mitogens and growth promotants in murine and
human hepatocellular carcinoma (5, 34), may have accelerated the growth of tumors
resulting from unrelated causes or background genetic mutations. Although limited
numbers of aged, nondiabetic male SW were available for study (n=4), no gross tumors
were seen in these mice or in aged nondiabetic females. Diabetic SW mice should
provide a useful model to explore the mechanisms behind liver carcinogenesis
associated with NAFLD in the diabetic state.
Additionally, in some aged mice with extensive HCC, a reversion to euglycemia or
hypoglycemia was observed (data not shown). Hypoglycemia can occur in humans with
HCC as a paraneoplastic syndrome associated with the production of insulin-like growth
factors and/or through progressive malnutrition and increased glucose demands by
neoplastic tissue (46). Generally, hypoglycemia associated with HCC is a poor
prognostic indicator.
Selected diabetic male Swiss Websters (SW) also showed histologic evidence of
glomerulopathy independent of bacterial infection at less than 6 months of age,
including basement membrane thickening and expansion of the mesangial matrix. This
is similar to other mouse models of spontaneous diabetic nephropathy, including the
db/db mouse (35); however, unlike the db/db mouse, the diabetic SW mice in this study
lived beyond 12 months of age without food restriction and provide a useful model to
study the natural progression of diabetic nephropathy. The diabetic SW mice also
revealed more severe diabetic kidney disease including membranous glomerulopathy
as the animals aged. In these mice, the degree and progression of renal insufficiency, a
feature lacking from most spontaneous mouse models of diabetes (9), will require
further studies.
Diabetic SW mice were also prone to bacterial infections of the urinary tract, in some
cases resulting in severe renal disease. Mixed infections by opportunist bacteria were
frequently cultured from kidney lesions and urine, including species of bacteria that are
associated with urinary tract infection in human diabetics (8) and in mouse models of
T2D (38).
Although diabetic mice had moderately to markedly dilated gastrointestinal tracts, most
notably in the cecum, no degenerative lesions were observed within small intestinal or
cecal myenteric plexi by light microscopy. However, electron microscopy and
immunohistochemical staining may be required to demonstrate lesions of the autonomic
nervous system consistent with diabetic neuropathy (26). It is also possible that
functional perturbances to intestinal motility unassociated with morphologic changes
(e.g. to interstitial cells of Cajal) may play a role in the flaccid paralysis of the bowel that
was a consistent gross feature of the diabetic males we analyzed. Similar gross lesions
have been observed in diabetic rats (22, 23), proposed as a model of gastrointestinal
autonomic neuropathy-a complication commonly seen in humans with type I diabetes
(insulin-dependent) mellitus. Signs of digestive dysfunction and delayed gastric
emptying (gastroparesis) have also been described in human diabetics and mouse
models of T2D (4, 21). Gastroparesis without overt diabetes has also been noted by us
in SW female mice (16).
Clinical signs of T2D were not observed in female SW mice. Male predilection for
diabetes is commonly reported in mouse models of spontaneous T2D, and may be due
to the lack of protective effects of estrogen. In humans, prevalence and progression of
diabetes increases in patients with conditions that result in decreased estrogen levels
such as polycystic ovarian syndrome and menopause. Studies in humans and mice
have also shown that estrogen replacement therapy improves glycemic control and
decreases the incidence of diabetes (24).
Female SW mice displayed increased abdominal fat deposition by 10 weeks of age
(>30g BW) and marked obesity by 6 months (>50g BW). While overt signs of diabetes
were not observed, obese females occasionally developed gallstones without a
cholesterol component (assessed by light microscopy utilizing a polarized light filter)
that were consistent with either black or brown pigment stones. Gallstones are also
seen with increased frequency in human diabetics and are thought to result from
gallbladder hypomobility and decreased emptying associated with reduced
cholecystokinin-A receptor expression in biliary smooth muscle (12).
Although the female SW in our study consistently produced offspring between 2-4
months of age, no females became pregnant when bred after 8 months of age. This
may be due to severe obesity rather than reproductive senescence. Dietary-induced
obesity has been shown to reduce fertility by more than 60% in female DBA/2J mice
with no effect on male fertility associated with hyperleptinemia and hypothalamic
hypogonadism (40). In db/db and ob/ob females, fertility is disrupted by mutation-
induced hypercytolipidemic utero-ovarian involution (17); however, histologic evidence
of reproductive dysfunction was not found in the SW females. Also, no evidence of
gestastional diabetes was seen in pregnant SW females. The high successful
pregnancy rate of the SW females less than 6 months of age, combined with their ability
to successfully raise litters provides an advantage over infertile mouse models of T2D
such as the db/db mouse.
The diabetic SW mice in this study share many features common to other mouse
models of T2D including moderate obesity, maturity onset glucosuria and nephropathy.
Importantly, additional, relevant features including high reproductive performance, a
strong pancreatic islet cell response to the diabetic state as evidenced by islet
metaplasia, and relatively early-onset kidney disease with biochemical evidence of renal
insufficiency; all of which make this model particularly useful (Table 3).
Additionally, the reproductive ability of the female SW and variable alterations in the
serum leptin concentrations of SW males, suggest that the leptin/leptin receptor axis is
not primarily involved in the pathogenesis of T2D in this model-similar to human T2D,
Table 3: Features of type 2 diabetes in selected spontaneous mouse models
Feature diabetic SW db/db KKAy  NONcNZO1 O/LtJ
Outbred Yes No No No
Fertile Yes No No Yes
Obesity Moderate Moderate-severe Severe Moderate
Hyperglycemia Moderate Severe Severe Variable
Leptin Variable Increased Variable Variable
Nephropathy Yes Yes Yes ?
Neuropathy ? Yes Yes ?
Polygenic ? No Yes Yes
and unlike the widely used db/db and ob/ob mice. Other important characteristics
include the SW mice's outbred background, and potentially the presence of autonomic
neuropathy suggested by cecal and intestinal dilation, despite the lack of neuronal
lesions visible by light microscopy. Importantly, the diabetic SW spontaneously
develops late-onset HCC making them particularly useful for the study of diabetes-
associated carcinogenesis.
Pathogenesis of diabetes in the SW follows a predictable course. At an early age,
diabetic mice weigh significantly more than their nondiabetic counterparts and develop
hyperglycemia at around 18 weeks of age. In mice less than six months of age, the
pancreas attempts to compensate for disease by increasing the production of insulin,
resulting in the presence of megaislets, pancreatic transdifferentiation and suspected
islet neogenesis. As disease progresses, hyperinsulinemia is more prominent until the
point of pancreatic decompensation, after which severe hyperglycemia may result
(>400mg/dl) as insulin levels decrease. At approximately six months of age, diabetic
comorbidities such as kidney and liver disease become apparent in diabetic males. By
12 months of age, most affected mice are entering end stage disease with progressive
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cachexia, pancreatic disease and liver disease (hepatosteatosis with hepatocellular
degeneration and hepatocellular carcinoma). In end stage diabetes, the pancreas may
exhibit zymogen depletion and chronic exocrine pancreatitis due to suspected enzyme
leakage from ectactic pancreatic ducts.
The genetic and physiologic mechanisms underlying the diabetic syndrome in this
cohort of SW mice remain unknown and are the subjects of further investigation. SW
mice retain the ability to breed, are normophagic and have variable serum levels of
leptin. In the diabetic SW, serum leptin appears to be more dependent on body
condition: as diabetes progresses, blood glucose increases and fat stores are depleted,
serum leptin is also diminished. Other mechanisms may involve genes important in the
transcription regulatory networks governing the liver and pancreatic islets such as the
HNF transcription factors. HNFla, HNF4a and HNF6 are all required for the normal
function of the liver and pancreas, and HNFla and HNF4a mutations are known to
cause maturity-onset diabetes of the young (MODY) in humans (43). The dual
involvement of the liver and pancreas in the dSW mice is suggestive of genetic defect
affecting both liver and pancreas development; however, unlike some transgenic
models of HNF dysfunction in mice that develop T2D and significant liver dysfunction
early in life (44), the dSW mice develop liver pathology only after the development of
late-stage diabetes.
In conclusion, while this cohort of outbred SW male mice shares some physiologic and
biochemical similarities with other mouse models of T2D, differences in parental
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background, reproductive capacity and pancreatic response to disease make it a
promising new model of the metabolic syndrome, T2D and their comorbidities in
humans. Further studies regarding the genetics and pathogenesis of the metabolic
syndrome and T2D in this model are in progress.
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Part 4: Future Directions
Part 3 demonstrated unique and clinically relevant features of a novel mouse model of
T2D and diabetic comorbidities including liver cancer in humans. While the study
represents a thorough clinical description of diabetic features in the dSW mice, further
study is required to completely characterize the model, physiologically and genetically.
Although these studies were beyond the scope of this project, Part 4 proposes a series
of experiments aimed at complete characterization of the dSW mice and is presented in
a grant-based format.
Part A: Specific Aims
The overall goal of this project is to determine the pathogenesis of type II diabetes
(T2D) in the diabetic Swiss Webster mouse (dSW) and thus validate it as a model of
human T2D and its comorbidities, including liver disease. Additionally, the project will
identify mechanisms in the pathogenesis of features unique to the model compared with
other mouse models of T2D, including the development of hepatocellular carcinoma and
pancreatic islet neogenesis/metaplasia.
Specific Aim 1: To determine what metabolic pathways are responsible for the
development of murine T2D in the dSW
Aim 1.1: Measure parameters associated with the metabolic syndrome to
determine risk factors associated with murine T2D
Metabolic syndrome is a known risk factor for the development of T2D in humans
and involves perturbations in lipid and glucose homeostasis, and inflammatory
pathways. Studies will be undertaken to measure parameters of the metabolic
syndrome as defined by the National Cholesterol Education Program's Adult
Treatment Panel III report (ATP III) at various ages in diabetic SW (dSW) and
nondiabetic SW (nSW) to determine if similar risk factors predict the development
of T2D in this mouse model. Furthermore, biomarkers of T2D risk may also be
identified.
Aim 1.2: Determine the influence of mitochondrial dysfunction on lipid
accumulation in somatic cells
Next, studies will be undertaken to determine the mechanisms behind lipid
accumulation in dSW hepatocytes, adipocytes and skeletal muscle cells.
Specifically, genetic mutations and mitochondrial dysfunction will be addressed.
Aim 1.3: Determine the mechanisms of insulin resistance (IR) in
hepatocytes and skeletal muscle
Studies will be undertaken to elucidate the insulin signaling pathway from ligand-
receptor interactions to intracellular signaling in both dSW and nSW in an effort
to understand the mechanisms of IR in the model, utilizing novel techniques in
mass spectrometry.
Aim 1.4: Determine the influence of environmental factors such as diet on
the pathogenesis of IR and T2D
Excessive dietary fat has been associated with acceleration in the progression
and severity of T2D in both human and rodent models. Mice will be fed a high fat
or western diet and compared with control and diet-restricted mice to determine
the influence of non-hereditary factors in the progression of T2D and its
comorbidities.
Specific Aim 2: To determine the mechanisms of liver carcinogenesis
(hepatocellular carcinoma) in the dSW
Aim 2.1: Determine the frequency of genetic mutations in hepatocytes
The diabetic phenotype will be crossed onto a mutation reporter mouse line
(BigBlue Assay) and liver cells will be collected to determine mutation frequency.
If the transfer of the MIT-SW phenotype is unsuccessful, BigBlue mice will
undergo diabetes induction through the administration of streptozotocin with
subsequent analysis of hepatocytes
Aim 2.2: Determine the influence of DNA repair mechanisms on the
development of diabetes-associated hepatocellular carcinoma in dSW
DNA repair mechanisms will be studied in neoplastic and normal hepatocytes of
dSW and nSW.
Aim 2.3: Determine the influence of dietary and pathogen-mediated factors
on the incidence of diabetes-associated hepatocellular carcinoma in dSW
dSW and nSW mice will be fed a high fat diet and compared to control and diet
restricted animals to observe for differences in tumor incidence and morphology,
as well as the progression/severity of nonalcoholic fatty liver disease (NAFLD).
Inflammation, if present, will be assessed by qPCR analysis of mRNA for genes
crucial in the inflammatory response.
Specific Aim 3: To determine the mechanisms of pancreatic response to IR and
T2D in the MIT-SW
Pancreatic islet cells from normal, hyperplastic, neogenic and metaplastic islets from
dSW and nSW will be isolated to determine the insulin production and response to
exogenous glucose. Messenger RNA from these pancreatic islet cells will be isolated
and subjected to microarray analysis to determine the up- and down-regulation of
various genes important in the development and function of pancreatic beta cells.
Part B: Background and Significance
Disease Epidemiology and Significance
Despite increased awareness of the obesity epidemic and a higher incidence of the
metabolic syndrome in humans, the incidence of obesity and its comorbidities-most
notably, type II diabetes (T2D) and cardiovascular disease (CVD)--continues to
increase in both adults and adolescents(Rosenbaum, Nonas et al. 2004). Metabolic
syndrome is characterized by the presence of at least three of the following risk factors:
abdominal obesity, dyslipidemia, hypertension, insulin resistance, a proinflammatory
state (elevated C-reactive protein), and a prothrombotic state (elevated plasma
plasminogen activator inhibitor) (Grundy, Brewer et al. 2004). A majority of affected
humans are obese and insulin resistant, conferring an increased risk for T2D (Grundy,
Brewer et al. 2004). Humans with T2D have a relative insulin deficiency characterized
by fasting hyperglycemia due to peripheral insulin resistance combined with an insulin
secretory defect (i.e. inability to increase beta cell mass). An estimated 5-10% of the
U.S. population suffers from T2D (Gregg, Cadwell et al. 2004; Sullivan, Morrato et al.
2005) and are at an increased risk for developing microvascular and neuropathic
complications, macrovascular disease, microbial infections and neoplasia. Together
with diabetic complications, T2D accounts for more than 92 billion dollars in direct
health care costs in the U.S. alone with an additional 40 billion in indirect medical
expenses (Yach, Stuckler et al. 2006).
Mouse Models of Type 2 Diabetes
Several spontaneous and induced genetic mutations resulting in varying degrees of
obesity and diabetes have been described in mice, making them popular models in
diabetes research (Accili 1995; Rees and Alcolado 2005). Mutation of the leptin or leptin
receptor gene produces obesity and T2D in the ob/ob and db/db mouse respectively.
The db/db mutation is available on a variety of mouse strain backgrounds, is well
characterized, and displays many of the comorbidities of T2D found in humans,
including cardiovascular disease, renal disease and neuropathies (Robertson and Sima
1980; Sharma, McCue et al. 2003; Ye, Donthi et al. 2005). However, these mice
represent a monogenic model demonstrating features related to leptin resistance,
including morbid obesity, hyperphagia, and alterations in thermoregulation and fertility.
In contrast to popular mouse models of diabetes, common forms of T2D in humans are
considered polygenic disorders, occurring through the simultaneous action of several
genes and rarely involving alterations of the leptin/leptin receptor axis. Despite the wide
availability of numerous rodent models of T2D, no mouse model completely
recapitulates human T2D or the metabolic syndrome and therefore, novel animal
models are desired.
Much of the morbidity and mortality associated with diabetes is a result of various
diabetic complications affecting numerous tissues including the liver, gastrointestinal
tract, neuronal tissues and the kidney. However, mouse models of diabetic
comorbidities are incomplete and no single mouse model consistently develops the full
spectrum of diabetic complications. For example, while renal insufficiency is common in
human cases of diabetic nephropathy, has not been shown to reliably occur in mice,
despite the presence of kidney lesions (Sharma, McCue et al. 2003). Improved animal
models in these realms could facilitate preclinical testing of diagnostic, preventive or
therapeutic interventions.
Insulin Resistance and Mitochondrial Dysfunction
Insulin resistance has been recognized as the fundamental underlying metabolic defect
in the pathogenesis of metabolic syndrome, a clustering of risk factors for heart disease
and T2D that include central obesity, dyslipidemia and hypertension (Grundy, Brewer et
al. 2004). Recent studies have linked mitochondrial dysfunction to the development of
insulin resistance and obesity in humans, demonstrating abnormal mitochondrial
structure, number and gene expression in diabetic patients and their
offspring(Wiederkehr and Wollheim 2006). Mitochondrial DNA (mtDNA) mutations are
also known to cause diabetes by affecting insulin secretion from pancreatic beta cells
(Nomiyama, Tanaka et al. 2004). Furthermore, humans and animal models of obesity
and insulin resistance show improvement in insulin sensitivity and fat metabolism when
treated with substances that enhance the function of mitochondria (Gumieniczek,
Hopkala et al. 2006; Waugh, Keating et al. 2006) such as pioglitazone, a peroxisome
proliferator-activated receptor gamma (PPAR y) agonist.
Deciphering the role that mitochondria play in the development of insulin resistance is
confounded by the influence of obesity on mitochondrial function. Obesity in rodent
models has been shown to significantly reduce the numbers of mitochondria within
adipocytes as a result of the expanding fat droplet displacing cellular organelles (Choo,
Kim et al. 2006). Additionally, cellular lipid accumulation and changes in fatty acid
metabolism that occur in the insulin resistant state leads to an increased cellular
oxidative stress (Lin, Berg et al. 2005). The generation of free radicals further damages
the highly sensitive mitochondria, resulting in further dysfunction and promotion of
insulin resistance and thus, accumulation of cellular lipids. This leads to an
augmentative cycle of increased cellular lipid accumulation, increased free radical
damage and increased insulin resistance. Oxidative stress and the release of reactive
oxygen species (ROS) promote inflammation through activation of NF-KB and have also
been implicated in the progression of diabetes complications, including microvascular
and macrovascular dysfunction and liver disease (Lin, Berg et al. 2005).
Liver Disease and Type 2 Diabetes
Diabetes mellitus, obesity and hepatosteatosis are known risk factors for development
of liver disease in human populations (EI-Serag 2004; Davila, Morgan et al. 2005;
Harrison 2006), including nonalcoholic fatty liver disease (NAFLD), nonalcoholic
steatohepatitis (NASH), glycogenic hepatopathy, cryptogenic cirrhosis and
hepatocellular carcinoma (HCC). Despite the known association, studies regarding the
mechanisms of liver carcinogenesis in the diabetic/insulin resistant state are lacking.
Regardless of the mechanism, hyperinsulinemia and insulin resistance have been
shown to be pro-inflammatory and profibrinogenic in the liver (Bugianesi, McCullough et
al. 2005) and insulin is a known growth promotant for isolated hepatocellular carcinoma
cells (Saito, Inoue et al. 2002; Boissan, Beurel et al. 2005). Further research into
mechanisms of liver carcinogenesis associated with diabetes and the metabolic
syndrome may uncover additional biomarkers and novel drug targets in human
populations.
Part C: Preliminary Studies
Background:
Discovery of Diabetic Swiss Webster Mice at MIT
We previously identified a cohort of male, outbred Swiss Webster (SW) mice in an MIT
breeding colony that required frequent cage changes due to urine-impregnated bedding,
and more frequent water bottle changes (i.e. polyuria/polydipsia). Five males were
isolated from the colony for further study. Metabolic comparisons with age-matched,
control males showed markedly increased urine production and water consumption in
the affected mice; however, there were no significant differences in food consumption or
body weight (data not shown). Additionally, affected mice were glucosuric, and serum
chemistry analysis with insulin levels on one mouse revealed hyperglycemia,
hypercholesterolemia, azotemia and hyperinsulinemia-signs consistent with both
metabolic syndrome and T2D in humans. Histopathology of selected affected mice
revealed no evidence of insulinitis or pancreatic pathology.
Part D: Research Design and Methods
Routinely used methods
The following methods will be routinely used and thus are described here and referred
to throughout the proposal.
Blood collection and determination of blood glucose concentration
Whole blood is collected from unanesthetized mice following an overnight fasting period
via puncture of the submandibular vascular bundle using an appropriately sized mouse
lancet (Medipoint Inc, Mineola, NY). When necropsies are performed, whole blood is
collected from fasted mice via cardiac puncture, immediately following euthanasia.
Blood glucose concentration is determined from whole blood utilizing a bedside
glucometer (LifeScan Inc, Miltapas, CA).
Husbandry, Monitoring of body weight and urinary glucose
Mice will be housed in polycarbonate microisolator cages on hardwood bedding
(PharmaServ, Framingham, MA) under specific pathogen free (SPF) conditions (free of
Helicobacter spp., Citrobacter rodentium, Salmonella spp., endoparasites, ectoparasites
and known murine viral pathogens) in an Association for the Assessment and
Accreditation of Laboratory Animal Care International (AAALAC) accredited facility.
Mouse rooms will be kept at constant temperature and humidity on a 12:12 hour light to
dark cycle. Mice will be regularly weighed and manually restrained to obtain free-catch
urine samples. These samples will be directly applied to urinary glucose test strips
(Diastix®) for determination of the presence or absence of urinary glucose according to
the manufacturer's instructions.
Dietary manipulation
Mice receiving the high fat diet (HFD) will be weaned at three to four weeks of age and
placed on a western-styled diet (TestDiet 5TJN: 40 kcal% fat) manufactured by Purina
Mills (St. Louis, MO) until the termination of study. The '"Western" diet for rodents is
based on AIN-93G contains 4.49 kcal/g with 20% fat (providing 30% of fat from lard,
30% from butterfat, 30% from hydrogenated vegetable oils, and for esterified fatty acids,
7% from soybean oil and 3% from corn oil), 49.5% carbohydrates, and 18.3% protein.
Approximate energy (kcal) is from fat 40%, carbohydrate 44%, protein 16% (protein:fat
= 2:5) with 0.15% cholesterol added. Those animals receiving control diets are fed the
standard mouse diet 5015 manufactured by Purina Mills (St. Louis, MO) until the
termination of study. The standard diet contains 3.73 kcal/g, with10% fat, 53.5%
carbohydrates, and 17.5% protein. Approximate energy (kcal) is from fat 25.8%,
carbohydrates 55.9% and protein 18.3%. Mice receiving dietary restriction will be fed
70% of the consumption (30% dietary restriction) of the control diet fed mice according
to standard protocols. Diet restriction mice will not be allowed to fall below 75% of the
expected body weight based on the control diet fed counterparts.
Specific Aim 1: To determine what metabolic pathways are responsible for the
development of murine T2D in the dSW
Aim 1.1: Measure parameters associated with the metabolic syndrome to
determine risk factors associated with murine T2D
Background
As demonstrated in our preliminary studies, the dSW mice develop evidence of the
metabolic syndrome similar to humans, including obesity, insulin resistance and
hyperlipidemia. To determine if dSW develop the full spectrum of criteria for the
diagnosis of metabolic syndrome or subsets of risk factors that will predict the
development of T2D, dSW and nSW will undergo rigorous metabolic characterization to
include blood pressure analysis, serum lipid analysis and characterization of a whole
body inflammatory and prothrombotic states.
Experimental Methods
Aim 1.1 will be executed in conjunction with Aim 1.4 to determine the influence of high
fat diet on these risk factors. All mice tested will originate from the segregated diabetic
colony at MIT housed under SPF conditions and will include animals from generation 5
and beyond. Animals will be divided into 2 experimental groups and 1 control group,
each containing 10 males and 10 females from the diabetic and 10 males and 10
females from the nondiabetic lines (n=120 mice total). The control group will be
maintained on ad libitum standard rodent chow, and the HFD and RD groups will be fed
as previously described. Individual animals will be subject to longitudinal studies with
time points at 3 months (prediabetic) and 6 months (diabetic). The following parameters
will be assessed: whole body composition (fat analysis), systolic blood pressure, and
rodent multi-analyte serology (59 plasma biomarkers of inflammation and metabolic
homeostasis, including C-reactive protein, apolipoprotein, fibrinogen, leptin and insulin).
Particular attention will be paid to markers of inflammation to assist in the diagnosis of
metabolic syndrome. Following the 6 month assessment, half of the animals will be
humanely euthanatized using C02 overdose and tissues collected for histopathological
analysis to monitor the development of T2D comorbidities such as liver, kidney and
gastrointestinal disease. The remaining animals will be aged to 12 months, after which
they will be euthanatized and tissues collected for histopathology.
Body composition analysis
Body composition will be measured in tribromoethanol-anesthetized mice using a dual
energy X-ray absorptiometry (DEXA) scanner from Lunar/GE Medical Systems
(PIXImus2, distributed by Faxitron X-Ray Corporation, Wheeling, IL), following an
overnight fasting period. Values for whole body bone mineral density, bone mineral
content, bone area, total tissue mass, total area, fat content, lean content and percent
fat (fat content divided by total tissue mass) will be obtained. Additionally, regions of
interest such as the abdominal cavity, may be isolated and analyzed separately by
DEXA software for determination of abdominal obesity. DEXA scanning methods have
been validated in mice by commercial laboratories (Jackson Labs, Bar Harbor, ME) and
individual investigators in obesity-related research (Nagy and Clair 2000).
Discrepancies in percent fat content of mice due to variations in tissue hydration will be
addressed by calculation of prediction equations for fat content and lean content based
on chemical analysis of whole body composition (Pietrobelli, Wang et al. 1998).
Rodent multi-analyte testing
Whole blood will be collected as previously described into
EDTA plasma collection tubes. 50pL of plasma will be used to
analyze 59 plasma biomarkers (Table 4) utilizing antigen-
capture immunofluorescence Luminex technology (Luminex
Corp, Austin, TX). Plasma lipid profile will also be assessed
for triglycerides, cholesterol and chylomicrons (VLDL, LDL,
HDL). Data mining will then be performed using a software
program from OmniViz, Maynard, MA, that groups samples by
their similarities in analyte expression patterns to generate a
unique chemical signature using the concentration of the
analytes measured in each sample. The relationship of each
sample signature is then determined in a proximity map
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Systolic blood pressure monitoring
Systolic blood pressure will be determined using the Visitech BP-2000-M4 Noninvasive
Blood Pressure Analysis System (Visitech, Cary, NC). Following a 5-day training period
to limit stress influences on blood pressure, mice will be tested over a three-day period
at the same time every testing day. Blood pressure measurements will be averaged
over the three days.
Glucose Tolerance Testing (Insulin Resistance)
After an overnight fasting period, a small amount of blood will be collected from the
lateral saphenous vein (lateral tail vein will not be used due to sample site variations in
biochemical parameters) to obtain a baseline blood glucose concentration as previously
described. Following baseline measurements, each mouse is challenged with 1.5mg
glucose/gram body weight (75mg/mL D-glucose stock solution) injected
intraperitoneally. Twenty minutes following the glucose injection, blood is obtained from
the previous bleeding site and a post-challenge blood glucose measurement is
obtained. Insulin resistant mice are expected to have higher blood glucose values post-
challenge and a longer time to return to baseline.
Aim 1.2: Determine the influence of mitochondrial function on lipid accumulation
in somatic cells (adipose, liver, heart, skeletal muscle)
As demonstrated in preliminary studies, dSW display increased body weight early in the
disease process and body weight is a key determinant in onset of diabetes mellitus and
glucosuria. Recent human studies suggest that mitochondrial dysfunction may lead to
lipid accumulation in cells, and subsequently, numerous metabolic disorders including
obesity and insulin resistance. As lipid accumulation occurs, oxidative stress is
increased resulting in deteriorating mitochondrial function. Mouse experiments have
suggested decreased numbers of mitochondria in the db/db mouse adipocytes, but not
the ob/ob mouse. This aim hopes to identify mitochondrial dysfunction as a key
mechanistic etiology in the development of the obese and diabetic phenotypes
observed in the dSW. If mitochondrial dysfunction is found to occur in the dSW, further
identification of the pathways affected may identify additional genetic determinants of
T2D. Mitochondrial number and function will be examined in mice from the dSW and
nSW lines at 8-12 weeks of age (prior to onset of gross obesity) and at 6 months of age
(obese and diabetic). Five males and 5 females from each line will be assessed.
Mitochondria Quantification in Tissues
Mice will be humanely euthanatized using CO02 overdose and tissue from the liver,
epididymal or ovarian fat pad, cardiac, and gastrocnemius muscle will be collected and
fixed in 4% neutral buffered formalin. Tissues will be embedded in paraffin and
sectioned at 4pm, deparrafinized in xylene and rehydrated using 100% and 95%
ethanol. For mitochondrial staining, sections will be incubated with 250nmol/L
MitoTracker (Molecular Probes) for 1 hr at room temperature, then observed using
fluorescent microscopy. For quantification of mitochondria, 10X fields will be analyzed
using Openlab Image analysis software (Improvision Inc., Lexington, Massachusetts,
USA) with the results are expressed as the percentage of the total area of each tissue
section.
Mitochondrial Function Assays-Oxygen Consumption
Oxygen consumption is an indirect measure of metabolic activity in cells, dependent on
mitochondrial oxidative respiration. To assess this activity, oxygen consumption of
collected adipocytes, hepatocytes, myocardial and skeletal muscle cells will be
assessed using the BDTM Oxygen Biosensor System (BD Biosciences, San Jose, CA)
according the manufacturer's instructions. Briefly, isolated cells will be aliquotted into
the Biosensor plate in duplicate, sealed and analyzed using a PowerWave Select
multimode microplate spectrophotometer (Bio-Tek Instruments, Winooski, VT) at 1-
minute intervals for 60 minutes at an excitation wavelength of 485 nm and emission
wavelength of 630 nm.
Mitochondrial Function Assays-Fatty Acid Oxidation
Isolated adipocytes and hepatocytes will be aliquotted into 50-ml polystyrene tubes, and
[14C]palmitic acid (Perkin Elmer Life Sciences, Wellesley, MA) will be added to a final
concentration of 200 nCi/ml. Then, an uncapped Eppendorf tube containing a piece of
No. 1 Whatman filter paper soaked in 300 pl benzethonium hydroxide (Sigma-Aldrich,
St. Louis, MO) will placed inside each 50-mi tube and incubated 2 hours at 370C, after
which 12 M HCI will be added to the cells to release the [14C]02. Released [14C]02 will
be allowed to absorb to the filter paper overnight, then quantified by scintillation
counting of the filter paper.
Aim 1.3: Determine the mechanisms of insulin resistance (IR) in adipocytes,
hepatocytes, pancreatic islet cells and skeletal muscle
Recent advances in phosphoproteome analysis by mass spectrometry have allowed the
identification of protein phosphorylation events regulating signal transduction cascades
associated with insulin signaling. Numerous, previously unrecognized tyrosine
phosphorylation sites have been identified in normal adipocytes following temporal
insulin stimulation, implicating these proteins in insulin action. By utilizing similar
techniques in the dSW mice, insight into the mechanisms of insulin resistance may be
gained, and potentially novel defects may be discovered. This may identify novel drug
targets and biomarkers of T2D in humans. Analysis at various time points within the
pathogenesis of dSW T2D will be undertaken to identify early and late stage events in
the pathogenesis of insulin resistance resulting in T2D occurring in multiple tissues.
Additionally, pancreatic islets from dSW and nSW mice will be isolated to determine the
insulin production and response to exogenous glucose that may influence the insulin
resistance phenotype (rule in or rule out underlying defect in insulin secretion).
Concurrent with measurements of blood insulin concentration and blood glucose
concentration as assessed in previous subaims, prediabetic (normal insulin, normal
blood glucose), compensated diabetic (high insulin, normal to mild hyperglycemia
(<300mg/dL), and decompensated diabetic (variable insulin, hyperglycemia
(>300mg/dL) mice will be assessed.
Identification of Experimental Groups
As demonstrated in preliminary studies, no diabetic dSW males are identified prior to 10
weeks of age; however, 80-100% of these mice go on to develop phenotypic T2D.
Therefore, prediabetic mice will be selected at 10 weeks to include 10 male dSW, 5
female dSW (low standard deviation in dSW females). Age matched, gender matched
nSW will also be selected. At around 3-5 months of age, prediabetic males are identified
by rising insulin levels concurrent with glucose concentrations between 200-300mg/dL
with peak insulin seen around 300mg/dL. Therefore, at 4 months of age, dSW males will
be screened for blood glucose concentrations between 250-300mg/dL and 10 males will
be selected for study with 5 age-matched dSW females, 5 nSW males and 5 nSW
females. At 6-8 months of age, 80-100% of dSW males are diabetic with glucose
concentrations >400mg/dL. These mice will be similarly screened and selected for study
at blood glucose >400mg/dL.
Insulin Secretion from Isolated Pancreatic Islets
To separate pancreatic islets from mouse pancreata, mice will be humanely
euthanatized by CO2 overdose and pancreata collected. Collagenase digestion will be
performed and islets will be hand picked under a stereomicroscope to avoid exocrine
contamination. Islet cells will be cultured in a low-glucose Krebs solution containing (in
mM) 2.8 glucose, 102 NaCI, 5 KCI, 1.2 MgCI 2, 2.7 CaCl2, 20 HEPES, 5 NaHCO3, and 1
mg/ml BSA, pH 7.4 and incubated for 60 min to allow sufficient time for adjustments in
metabolism to occur. After 60 min, samples will be collected at 2-min intervals for 10
min, and then the low-glucose solution will be replaced with a high-glucose solution
containing (in mM) 11.1 glucose, 132 NaCI, 5 KCI, 1.2 MgCl2, 1 CaCl2, 10 HEPES, 5
NaHCO 3, and 1 mg/ml BSA, pH 7.3. Samples will then be collected at 2-min intervals for
the first 10 min and then at 5-min intervals for the next 20 min. Insulin concentration of
collected samples will be measured using a Rat/Mouse Insulin ELISA kit (LINCO
Research, St. Charles, MO) according to the manufacturer's instructions.
Identification of Insulin Signaling Pathways
Animals will be humanely euthanatized with C02 overdose and necropsied. Epididymal
or ovarian adipocytes, hepatocytes and gastrocnemius skeletal muscle will be collected
aseptically and individual cells isolated using standard methods. Cells will be stimulated
with exogenous insulin for 0, 5, 15, and 45min and subjected to lysis, digestion, clean-
up and analysis as previously described (Schmelzle, 2006). Briefly, samples will be
labeled with isobaric tags (iTRAQ) and tyrosine phosophorylated peptides
immunoprecipitated and enriched by immobilized metal affinity chromatography coupled
to tandem mass spectrometry. This will result in identification and relative temporal
quantification of tyrosine phosphorylation sites on proteins allowing assessment of
defective pathways.
Aim 1.4: Determine the influence of environmental factors such as diet on the
pathogenesis of IR and T2D
High fat diet and dietary restriction are shown to influence the pathogenesis of T2D in
genetically susceptible humans and rodents. Concurrent with Aim 1.1 animals will be
fed a high fat diet or undergo dietary restriction as previously described. Changes in
progression and severity of T2D comorbidities will also be addressed by biochemical
and histopathological analyses (see Aim 1.1).
Specific Aim 2: Determine the mechanisms of liver carcinogenesis (hepatocellular
carcinoma) in the dSW mouse
As shown in preliminary data, dSW develop hepatocellular carcinoma and varying
degrees of macrosteatosis and microsteatosis, making the dSW a model for liver
carcinogenesis in the diabetic state, and potentially, nonalcoholic fatty liver disease
(NAFLD). Diabetic humans also show an increased risk of HCC; however, little is known
regarding the mechanisms behind this increased risk. As a starting point for addressing
the mechanism behind liver carcinogenesis in T2D, the frequency of genetic mutations
and mechanisms of DNA repair in diabetic hepatocytes will be assessed. Additionally, to
fulfill Aims 1.4 and 2.3, high fat diet and dietary restriction will be used to determine
environmental influences on these mechanisms.
Aim 2.1: Determine the frequency of genetic mutations in hepatocytes
Big Blue® Transgenic mice (Stratagene, La Jolla, CA) have the LacZ and Lambda cll
genes incorporated into the genome, which allows researchers to efficiently package
DNA from any tissue of interest and determine a quantitative level of mutagenesis.
These mice will be used to asses the mutation frequency of hepatocytes in the dSW,
HCC-prone mice by crossing the diabetic phenotype onto the mutation reporter mouse
line. If the transfer of the dSW phenotype is unsuccessful, Big Blue" mice will undergo
diabetes induction through the administration of streptozotocin with subsequent analysis
of hepatocytes, to address the general role of T2D in liver mutagenesis.
Induction of T2D in Big Blue" Mice
Ten week old dSW males will be crossed with age-matched Big Blue@ C57BL/6 female
homozygous mice and the F1 offspring monitored for the development of glucosuria for
up to 6 months, concurrent with genotyping to ensure the continued incorporation of the
LacZ and Lambda cll genes. Diabetic Fls will be used to develop a line of diabetic Big
Blue@-Swiss Webster hybrids for future analysis. Alternatively, if difficulties arise with
maintenance of the transgenes in hybrid mice, dSW female mice crossed to Big Blue@
C57BL/6 males may be used. Concurrently, a line derived from the nSW mice will also
be developed. If breeding strategies prove unsuccessful in producing diabetic Big
Blue@-Swiss Webster hybrids, T2D will be induced in Big Blue@ mice by the
administration of streptozotocin utilizing standard methods (40mg STZ/kg body weight
intraperitoneally for five consecutive days) at 10 weeks of age. Once diabetes is
established in the Big Blue@ mice (dSW hybrids or STZ), offspring will be divided into
high fat diet, control diet and dietary restriction groups.
Quantification of Genetic Mutations in Hepatocytes of Diabetic Big Blue" Mice
Mice will be humanely euthanatized using CO2 overdose at 6 months of age and the left
lateral lobe of the liver will be collected for analysis at the lateral aspect. Genomic DNA
will be isolated from liver tissue using the High Pure PCR Template kit (Roche
Diagnostics, Pleasanton, CA). The LambdaSelect-cllTM mutation assay kit will be used
to quantitate mutation frequency based on the selection of mutations in the cll gene of
the E. coli phage lambda.1. The cll gene encodes a protein that activates transcriptional
promoters in lambda that are essential for lysogenization, and mutations in the clI
region that lower the levels of cll protein result in a decreased ability of lambda to
lysogenize. DNA will be packaged into the phage vector and grown under conditions
that favor lysogeny under selective and nonselective media. Lambda prophages that
carry mutations (cll-) will survive only by entering the lytic pathway, forming plaques (as
opposed to wild-type DNA, which becomes incorporated into the DNA of the bacterial
lawn). Therefore, only mutated phage can form plaques greatly reducing the odds of
obtaining ex vivo mutations (from E. coli and not model system). Mutation frequency will
be calculated by dividing the total lambda cll- plaque forming units (pfu) by the total
number of pfu's screened.
Aim 2.2. Determine the influence of DNA repair mechanisms on the development
of diabetes-associated hepatocellular carcinoma in dSW
Alterations in DNA repair mechanisms have been implicated in the pathogenesis of
HCC in humans with or without steatohepatitis; however, despite known oxidative
damage that occurs within hepatocytes during progression of NAFLD, little work has
addressed the role of DNA repair mechanisms in the development of HCC in diabetic
patients. Certain DNA mismatch repair (MMR) genes are highly conserved amongst
eukaryotes, including Msh2 (required for all mismatch correction in nuclear DNA), Msh3
(forms Msh2/ Msh3 heterodimers and plays the major role in recognition of mismatched
DNA in eukaryotic MMR), Msh6 (repair of distinct mismatched DNA during replication)
and MIh1. These genes have also been implicated in various gastrointestinal, epithelial
and other tumors of mice; therefore, gene expression of Msh2, Msh3, Msh6, and Mlhi
will be studied in neoplastic and normal hepatocytes of dSW and nSW undergoing
various dietary manipulations as described previously.
Gene Expression Anaylsis of Hepatocyte DNA Mismatch Repair (MMR) Genes
As shown in preliminary studies, dSW mice develop HCC at an increased frequency
compared with nondiabetic mice by 12 months of age. If tumors are present in mice
removed from study under Aim 1.1 at 12 months of age, mRNA will be collected from
neoplastic and normal tissue using the Qiagen RNeasy Micro Kit and converted to
cDNA utilizing Invitrogen SuperScript@ III First-Strand Synthesis SuperMix. Purified
cDNA will be analyzed via quantitative qPCR for the expression of murine Msh2, Msh3,
Msh6, and Mlhi, utilizing commercially available primers and probes (Applied
Biosystems). qPCR will be performed utilizing the Taqman@ 7700 system and genes of
interest normalized to Gapdh.
Aim 2.3: Determine the influence of dietary factors on the incidence of diabetes-
associated hepatocellular carcinoma in dSW
dSW and nSW mice fed a high fat diet or undergoing dietary restriction will be collected
from studies under previous aims to observe for differences in tumor incidence and
morphology, as well as the progression/severity of nonalcoholic fatty liver disease
(NAFLD). Inflammation, if present, will be assessed by qPCR analysis of mRNA for
genes crucial in the inflammatory response using commercially available probes as
described in Aim 2.2.
Specific Aim 3: To determine the mechanisms of pancreatic response to IR and
T2D in the MIT-SW
As demonstrated in preliminary studies, the dSW mice show a robust pancreatic
response to the diabetic state-most notably, areas of pancreatic islet metaplasia and
suspected neogenesis were observed. While these phenomena have been described in
diabetic humans and in rodent models of pancreatic injury, they have not been reported
in spontaneous mouse models of T2D. Investigation of the mechanisms driving the
pancreatic response to diabetes in the dSW mouse may identify novel pathways in the
pathogenesis of pancreatic islet degeneration and regeneration, and provide potential
biomarkers and drug targets for human T2D. To accomplish this aim, pancreatic islet
cells from normal, hyperplastic (mega-islets), metaplastic (exocrine to endocrine
transdifferentiation) and neogenic (endocrine cell clusters and tubular proliferation
adjacent to pancreatic ductules) from dSW and normal islet cells from nSW will be
isolated and messenger RNA from these pancreatic islet cells will be isolated and
subjected to microarray analysis to determine the up- and down-regulation of various
genes important in the development and function of pancreatic beta cells.
Identification of Pancreatic Islet and Exocrine Cells of Interest
Whole pancreata (to include the duodenal and gastric arms) will be collected from 6
month old dSW and nSW mice and flash-frozen in OCT media-filled cryomolds. Serial
sections at 4-8pm will be obtained. One section will be co-stained using standard
fluorescent immunohistochemical techniques with guinea pig anti-swine insulin antibody
(Riu, Ferre et al. 2002) (DakoCytomation, Carpinteria, CA) and _rabbit anti-pancreatic
amylase polyclonal antibody (Abcam, Cambridge, MA) at 1:150 on an automated
immunostainer as previously described (Rogers, Taylor et al. 2005). This slide will be
used to identify cells of interest for laser capture microdissection of the saved serial
section.
Isolation of RNA from Cells of Interest
The second section will be stained using standard histology methods with hematoxylin
and eosin (H&E). Cells of interest will be isolated using Laser Capture Microdissection
using standard protocols. The cap post laser transfer is placed tightly onto an Eppendorf
tube, and the tube is then inverted back and forth over the course of 2 minutes. It is then
quick spun to collect all of the buffer. Roughly 1,000-5,000 cells are extracted for mRNA
using the Qiagen RNeasy Micro Kit; however, if adequate samples cannot be obtained
for cells types, RNA amplification strategies may be employed. cDNA will then be
constructed utilizing Invitrogen SuperScript@ III First-Strand Synthesis SuperMix.
Purified cDNA will be analyzed via quantitative qPCR for the expression of murine Pdx-
1 (pancreatic and duodenal homeobox gene-1: pancreatic patterning and development),
EGF (epidermal growth factor), Ngn-3 (neurogenin-3: differentiation of endocrine cells),
Ptfla (pancreas transcription factor-la: ventral pancreatic development), Hlxb9
(homeobox transcription factor: dorsal pancreatic development), HNF1b (hepatocyte
nuclear factor-i b: pancreatic ductular cell development) and Mist-1 (acinar exocrine cell
development), utilizing commercially available primers and probes (Applied
Biosystems). qPCR will be performed utilizing the Taqman@ 7700 system and genes of
interest normalized to Gapdh.
Concluding Remarks and Future Directions
These studies are designed to further understand pathogenesis of T2D in the diabetic
Swiss Webster mouse (dSW) and thus validate it as a model of human T2D and its
comorbidities, including liver disease. Validation of the model will provide the research
community with a novel model of the metabolic syndrome and T2D, and may provide
additional mechanistic pathways resulting in the identification of novel biomarkers,
diagnostic and therapeutic targets. Of particular interest is the development of HCC in
the dSW, and although extensive genetic analyses are beyond the scope of this project,
a thorough understanding of the pathogenesis of disease in the dSW mouse could
identify genetic mutations that may play a role in human HCC.
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